Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Use of p16 immunohistochemical stain to help differentiate inflamed melanocytic nevi from metastatic melanoma in the setting of immunotherapy.

Adelman M, Lyons AB, Seale L, Friedman BJ.

J Am Acad Dermatol. 2019 Nov 22. pii: S0190-9622(19)33125-1. doi: 10.1016/j.jaad.2019.11.033. [Epub ahead of print] No abstract available.

PMID:
31765681
2.

A Randomized, Controlled, Split-Face Study of the Efficacy of a Picosecond Laser in the Treatment of Melasma

Lyons AB, Moy RL, Herrmann JL.

J Drugs Dermatol. 2019 Nov 1;18(11):1104-1107.

PMID:
31741350
3.

Circadian Rhythm and the Skin: A Review of the Literature.

Lyons AB, Moy L, Moy R, Tung R.

J Clin Aesthet Dermatol. 2019 Sep;12(9):42-45. Epub 2019 Sep 1. Review.

4.

Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa.

Turk D, Vellaichamy G, Lyons AB, Parks-Miller A, Nelson T, Meysami A, Hamzavi IH.

Int J Dermatol. 2019 Oct 21. doi: 10.1111/ijd.14674. [Epub ahead of print] No abstract available.

PMID:
31633193
5.

Disease Severity and Quality of Life Outcome Measurements in Patients With Keloids: A Systematic Review.

Lyons AB, Peacock A, Braunberger TL, Viola KV, Ozog DM.

Dermatol Surg. 2019 Dec;45(12):1477-1483. doi: 10.1097/DSS.0000000000002172.

PMID:
31567612
6.

Greater efficacy of SPF 100+ sunscreen compared to SPF 50+ in sunburn prevention during five consecutive days of sunlight exposure: A Randomized, Double-Blind Clinical Trial.

Kohli I, Nicholson CL, Williams JD, Lyons AB, Seo I, Maitra P, Tian X, Atillasoy E, Lim HW, Hamzavi IH.

J Am Acad Dermatol. 2019 Sep 19. pii: S0190-9622(19)32755-0. doi: 10.1016/j.jaad.2019.09.018. [Epub ahead of print]

PMID:
31542406
7.

Emerging Roles for G-protein Coupled Receptors in Development and Activation of Macrophages.

Wang X, Iyer A, Lyons AB, Körner H, Wei W.

Front Immunol. 2019 Aug 27;10:2031. doi: 10.3389/fimmu.2019.02031. eCollection 2019. Review.

8.

Long-wavelength Ultraviolet A1 and Visible Light Photoprotection: A Multimodality Assessment of Dose and Response.

Kohli I, Braunberger TL, Nahhas AF, Mirza FN, Mokhtari M, Lyons AB, Kollias N, Ruvolo E, Lim HW, Hamzavi IH.

Photochem Photobiol. 2019 Aug 29. doi: 10.1111/php.13157. [Epub ahead of print]

PMID:
31464341
9.

Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii).

Patchett AL, Coorens THH, Darby J, Wilson R, McKay MJ, Kamath KS, Rubin A, Wakefield M, Mcintosh L, Mangiola S, Pye RJ, Flies AS, Corcoran LM, Lyons AB, Woods GM, Murchison EP, Papenfuss AT, Tovar C.

Cell Mol Life Sci. 2019 Aug 2. doi: 10.1007/s00018-019-03259-2. [Epub ahead of print]

PMID:
31375869
10.

Impact of Long-Wavelength Ultraviolet A1 and Visible Light on Light-Skinned Individuals.

Kohli I, Zubair R, Lyons AB, Nahhas AF, Braunberger TL, Mokhtari M, Ruvolo E, Lim HW, Hamzavi IH.

Photochem Photobiol. 2019 Nov;95(6):1285-1287. doi: 10.1111/php.13143. Epub 2019 Aug 23.

PMID:
31344760
11.

Use of Autologous, Noncultured Melanocyte-Keratinocyte Transplantation in Patients With Stable Genital Leucoderma.

Lyons AB, Abbas Z, Mohammad TF, Hamzavi IH.

Dermatol Surg. 2019 Jul 22. doi: 10.1097/DSS.0000000000002032. [Epub ahead of print] No abstract available.

PMID:
31343442
12.

Topical chemotherapy for numerous superficial basal cell carcinomas years after isolated limb perfusion for melanoma.

Lyons AB, Mitchell DA, Moy RL.

Cutis. 2019 May;103(5):298-299. No abstract available.

PMID:
31233581
13.

Examining Infants' Individuation of Others by Sociomoral Disposition.

Taborda-Osorio H, Lyons AB, Cheries EW.

Front Psychol. 2019 May 31;10:1271. doi: 10.3389/fpsyg.2019.01271. eCollection 2019.

14.

Non-Invasive Buccal Swab Gene Testing for Skin Cancer Risk

Moy L, Lyons AB, Fox W, Glicksman MA, Moy R, Tung R.

J Drugs Dermatol. 2019 May 1;18(5):448-453.

PMID:
31141850
15.

Pregnancy protects against the pro-inflammatory respiratory responses induced by particulate matter exposure.

Thaver S, Bennett EJ, Foa L, Richards SM, Lyons AB, Zosky GR.

Chemosphere. 2019 Jun;225:796-802. doi: 10.1016/j.chemosphere.2019.03.088. Epub 2019 Mar 16.

PMID:
30904759
16.

What's New in Pigmentary Disorders.

Zubair R, Lyons AB, Vellaichamy G, Peacock A, Hamzavi I.

Dermatol Clin. 2019 Apr;37(2):175-181. doi: 10.1016/j.det.2018.12.008. Epub 2019 Feb 16. Review.

PMID:
30850040
17.

Insights on an in vivo model for postinflammatory hyperpigmentation.

Lyons AB, Kohli I, Lim HW, Hamzavi IH.

Br J Dermatol. 2019 Sep;181(3):598-599. doi: 10.1111/bjd.17746. Epub 2019 May 13. No abstract available.

PMID:
30729515
18.

Preoperative Ultrasound for Evaluation of Hidradenitis Suppurativa.

Lyons AB, Zubair R, Kohli I, Hamzavi IH.

Dermatol Surg. 2019 Feb;45(2):294-296. doi: 10.1097/DSS.0000000000001696. No abstract available.

PMID:
30726198
19.

Inducible IFN-γ Expression for MHC-I Upregulation in Devil Facial Tumor Cells.

Ong CEB, Lyons AB, Woods GM, Flies AS.

Front Immunol. 2019 Jan 14;9:3117. doi: 10.3389/fimmu.2018.03117. eCollection 2018.

20.

TNF May Negatively Regulate Phagocytosis of Devil Facial Tumour Disease Cells by Activated Macrophages.

Li X, Darby J, Lyons AB, Woods GM, Körner H.

Immunol Invest. 2019 Oct;48(7):691-703. doi: 10.1080/08820139.2018.1515222. Epub 2019 Jan 19.

PMID:
30663448
21.

Successful treatment of solar urticaria with UVA1 hardening in three patients.

Lyons AB, Peacock A, Zubair R, Hamzavi IH, Lim HW.

Photodermatol Photoimmunol Photomed. 2019 May;35(3):193-195. doi: 10.1111/phpp.12447. Epub 2019 Jan 8.

PMID:
30576021
22.

Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa- Reply.

Lyons AB, Parks-Miller A, Zubair R, Hamzavi IH.

Int J Dermatol. 2019 Apr;58(4):E88. doi: 10.1111/ijd.14329. Epub 2018 Dec 4. No abstract available.

PMID:
30515760
23.

Two Decades of the Impact of Tasmanian Devil Facial Tumor Disease.

Woods GM, Fox S, Flies AS, Tovar CD, Jones M, Hamede R, Pemberton D, Lyons AB, Bettiol SS.

Integr Comp Biol. 2018 Dec 1;58(6):1043-1054. doi: 10.1093/icb/icy118.

PMID:
30252058
24.

Dehydrated human amnion/chorion membrane allograft as an aid for wound healing in patients with full-thickness scalp defects after Mohs micrographic surgery.

Lyons AB, Chipps LK, Moy RL, Herrmann JL.

JAAD Case Rep. 2018 Aug 15;4(7):688-691. doi: 10.1016/j.jdcr.2018.03.015. eCollection 2018 Aug. No abstract available.

25.

Correction of cicatricial and involutional lower eyelid ectropion with hyaluronic acid.

Mitchell DA, Lyons AB, Moy RL.

JAAD Case Rep. 2018 Jul 20;4(7):628-630. doi: 10.1016/j.jdcr.2018.04.014. eCollection 2018 Aug. No abstract available.

26.

Heat shock proteins expressed in the marsupial Tasmanian devil are potential antigenic candidates in a vaccine against devil facial tumour disease.

Tovar C, Patchett AL, Kim V, Wilson R, Darby J, Lyons AB, Woods GM.

PLoS One. 2018 Apr 27;13(4):e0196469. doi: 10.1371/journal.pone.0196469. eCollection 2018.

27.

Maternal exposure to particulate matter alters early post-natal lung function and immune cell development.

Chen L, Bennett E, Wheeler AJ, Lyons AB, Woods GM, Johnston F, Zosky GR.

Environ Res. 2018 Jul;164:625-635. doi: 10.1016/j.envres.2018.03.029. Epub 2018 Apr 5.

PMID:
29627759
28.

Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release.

Pye R, Patchett A, McLennan E, Thomson R, Carver S, Fox S, Pemberton D, Kreiss A, Baz Morelli A, Silva A, Pearse MJ, Corcoran LM, Belov K, Hogg CJ, Woods GM, Lyons AB.

Front Immunol. 2018 Feb 19;9:259. doi: 10.3389/fimmu.2018.00259. eCollection 2018.

29.

Absence of Tumor Necrosis Factor Supports Alternative Activation of Macrophages in the Liver after Infection with Leishmania major.

Hu S, Marshall C, Darby J, Wei W, Lyons AB, Körner H.

Front Immunol. 2018 Jan 19;9:1. doi: 10.3389/fimmu.2018.00001. eCollection 2018.

30.

The toll-like receptor ligands Hiltonol® (polyICLC) and imiquimod effectively activate antigen-specific immune responses in Tasmanian devils (Sarcophilus harrisii).

Patchett AL, Tovar C, Corcoran LM, Lyons AB, Woods GM.

Dev Comp Immunol. 2017 Nov;76:352-360. doi: 10.1016/j.dci.2017.07.004. Epub 2017 Jul 6.

PMID:
28689773
31.

The absence of TNF permits myeloid Arginase 1 expression in experimental L. monocytogenes infection.

Li X, Lyons AB, Woods GM, Körner H.

Immunobiology. 2017 Aug;222(8-9):913-917. doi: 10.1016/j.imbio.2017.05.012. Epub 2017 May 16.

PMID:
28545808
32.

Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.

Flies AS, Blackburn NB, Lyons AB, Hayball JD, Woods GM.

Front Immunol. 2017 May 3;8:513. doi: 10.3389/fimmu.2017.00513. eCollection 2017.

33.

Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils.

Tovar C, Pye RJ, Kreiss A, Cheng Y, Brown GK, Darby J, Malley RC, Siddle HV, Skjødt K, Kaufman J, Silva A, Baz Morelli A, Papenfuss AT, Corcoran LM, Murphy JM, Pearse MJ, Belov K, Lyons AB, Woods GM.

Sci Rep. 2017 Mar 9;7:43827. doi: 10.1038/srep43827.

34.

An isolate of Haemophilus haemolyticus produces a bacteriocin-like substance that inhibits the growth of nontypeable Haemophilus influenzae.

Latham RD, Gell DA, Fairbairn RL, Lyons AB, Shukla SD, Cho KY, Jones DA, Harkness NM, Tristram SG.

Int J Antimicrob Agents. 2017 Apr;49(4):503-506. doi: 10.1016/j.ijantimicag.2016.12.010. Epub 2017 Feb 24.

PMID:
28242259
35.

Squamous Cell Carcinoma of the Lip-A Review of Squamous Cell Carcinogenesis of the Mucosal and Cutaneous Junction.

Bota JP, Lyons AB, Carroll BT.

Dermatol Surg. 2017 Apr;43(4):494-506. doi: 10.1097/DSS.0000000000001020. Review.

PMID:
28157733
36.

Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.

Pye R, Hamede R, Siddle HV, Caldwell A, Knowles GW, Swift K, Kreiss A, Jones ME, Lyons AB, Woods GM.

Biol Lett. 2016 Oct;12(10). pii: 20160553. doi: 10.1098/rsbl.2016.0553.

37.

PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.

Flies AS, Lyons AB, Corcoran LM, Papenfuss AT, Murphy JM, Knowles GW, Woods GM, Hayball JD.

Front Immunol. 2016 Dec 9;7:581. doi: 10.3389/fimmu.2016.00581. eCollection 2016.

38.

The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines.

Patchett AL, Darby JM, Tovar C, Lyons AB, Woods GM.

PLoS One. 2016 Dec 9;11(12):e0168068. doi: 10.1371/journal.pone.0168068. eCollection 2016.

39.

Mitogen-activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells.

Brown GK, Tovar C, Cooray AA, Kreiss A, Darby J, Murphy JM, Corcoran LM, Bettiol SS, Lyons AB, Woods GM.

Immunol Cell Biol. 2016 Aug;94(7):673-9. doi: 10.1038/icb.2016.38. Epub 2016 Apr 19.

PMID:
27089941
40.

Fluoroscopy-induced chronic radiation dermatitis (FICRD) after endovascular abdominal aortic aneurysm endoleak repair.

Lyons AB, Harvey VM, Gusev J.

JAAD Case Rep. 2015 Nov 23;1(6):403-5. doi: 10.1016/j.jdcr.2015.09.022. eCollection 2015 Nov. No abstract available.

41.

Oral melanoma in a gravid, HIV-positive woman.

Lyons AB, Warren MP, Ferguson C, Katdare M, Harvey VM.

JAAD Case Rep. 2015 May 2;1(3):120-2. doi: 10.1016/j.jdcr.2015.02.011. eCollection 2015 May. No abstract available.

42.

A second transmissible cancer in Tasmanian devils.

Pye RJ, Pemberton D, Tovar C, Tubio JM, Dun KA, Fox S, Darby J, Hayes D, Knowles GW, Kreiss A, Siddle HV, Swift K, Lyons AB, Murchison EP, Woods GM.

Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):374-9. doi: 10.1073/pnas.1519691113. Epub 2015 Dec 28.

43.

Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil.

Patchett AL, Latham R, Brettingham-Moore KH, Tovar C, Lyons AB, Woods GM.

Dev Comp Immunol. 2015 Nov;53(1):123-33. doi: 10.1016/j.dci.2015.07.003. Epub 2015 Jul 13.

PMID:
26182986
44.

Immunology of a Transmissible Cancer Spreading among Tasmanian Devils.

Woods GM, Howson LJ, Brown GK, Tovar C, Kreiss A, Corcoran LM, Lyons AB.

J Immunol. 2015 Jul 1;195(1):23-9. doi: 10.4049/jimmunol.1500131. Review.

45.

Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations.

Kreiss A, Brown GK, Tovar C, Lyons AB, Woods GM.

Vaccine. 2015 Jun 12;33(26):3016-25. doi: 10.1016/j.vaccine.2015.01.039. Epub 2015 Feb 20.

46.

CC Chemokine Ligand 20 and Its Cognate Receptor CCR6 in Mucosal T Cell Immunology and Inflammatory Bowel Disease: Odd Couple or Axis of Evil?

Lee AY, Eri R, Lyons AB, Grimm MC, Korner H.

Front Immunol. 2013 Jul 15;4:194. doi: 10.3389/fimmu.2013.00194. eCollection 2013.

47.

Flow cytometric analysis of cell division by dilution of CFSE and related dyes.

Lyons AB, Blake SJ, Doherty KV.

Curr Protoc Cytom. 2013;Chapter 9:Unit9.11. doi: 10.1002/0471142956.cy0911s64. Review.

PMID:
23546777
48.

Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.

Blake SJ, Hughes TP, Lyons AB.

Exp Hematol. 2012 Aug;40(8):612-21.e6. doi: 10.1016/j.exphem.2012.04.003. Epub 2012 Apr 19.

PMID:
22521768
49.

Natural killer cell mediated cytotoxic responses in the Tasmanian devil.

Brown GK, Kreiss A, Lyons AB, Woods GM.

PLoS One. 2011;6(9):e24475. doi: 10.1371/journal.pone.0024475. Epub 2011 Sep 21.

50.

Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro.

Blake SJ, Lyons AB, Hughes TP.

J Cell Mol Med. 2009 Mar;13(3):599-601. doi: 10.1111/j.1582-4934.2009.00500_1.x. No abstract available.

Supplemental Content

Loading ...
Support Center